



Media Contact:

Elizabeth Somers

Director, Business Development

Fujirebio Diagnostics, Inc.

610-240-3812

[somerse@fujirebiodiagnostics.com](mailto:somerse@fujirebiodiagnostics.com)

Dennis Tartaglia

M Booth & Associates, Inc.

212-481-7000

[dennist@mbooth.com](mailto:dennist@mbooth.com)

Karen Peart

Yale University

203-432-1326

[karen.peart@yale.edu](mailto:karen.peart@yale.edu)

**FOR IMMEDIATE RELEASE**

**FUJIREBIO DIAGNOSTICS OBTAINS RIGHTS FROM YALE UNIVERSITY TO DEVELOP CANCER DIAGNOSTICS UTILIZING SURVIVIN MOLECULE**

**Malvern, Pa. and New Haven, Ct. March 4, 2002** – Fujirebio Diagnostics, Inc. (FDI), a leading oncology diagnostics company, and Yale University, today announced an agreement in which FDI has acquired the rights to develop and commercialize cancer diagnostic tests based on the cancer-specific gene Survivin.

The Survivin gene has been chosen by FDI for development because of its specific expression in tumor tissues. Survivin has potential use as a diagnostic test for bladder cancer as demonstrated in preliminary clinical studies published by investigators led by Dario Altieri, M.D., Professor of Pathology, Boyer Center for Molecular Medicine, Yale University School of Medicine.

“The Survivin gene has attracted considerable attention in oncology for its abundant expression in cancer but not in normal tissues,” stated Dr. Altieri. “Survivin is thought to shield tumor cells from a physiological process of cell death called apoptosis and to promote tumor cell proliferation. For its almost selective expression in cancer and not in normal tissues, Survivin is a potentially ideal diagnostic tool. This concept has been validated in bladder cancer, where the presence of Survivin in urine may help identify with considerable accuracy patients carrying the disease or at risk of recurrences after treatment.”

Under the terms of the agreement, FDI has acquired from Yale University worldwide rights to develop and commercialize cancer diagnostics based on Survivin. The agreement also includes diagnostic rights for therapeutic drug monitoring. In return, FDI will provide Yale with license fees, milestone payments and royalties on future product sales.

“The agreement with Yale to obtain the rights to develop cancer diagnostic tests utilizing the Survivin molecule is an important addition to our new product pipeline of promising oncology diagnostics,” stated Aris Petropoulos, President and Chief Operating Officer,

Fujirebio Diagnostics. “We are enthusiastic about the potential of this marker as well as the future collaboration with Yale.”

“Our goal is to develop a diagnostic test for bladder cancer which will have the performance characteristics necessary to meet the needs of physicians for the diagnosis and management of this disease,” said Daniel J. O’Shannessy, Ph.D., FDI’s Chief Scientific Officer. “Bladder cancer is sorely lacking in reliable tests for detection of disease. Given Survivin’s pivotal role in inhibiting cell death, a hallmark of all cancers, it may have utility in the diagnosis, prognosis or monitoring of other cancers as well.”

“The Yale-FDI agreement is a wonderful example of a collaboration and synergy between industry and academia, and one that is likely to quickly benefit patients with bladder cancer,” said Dr. Altieri. “We are ecstatic at the signing of the agreement; it reflects a major effort in oncology to quickly move into the clinic the most recent scientific advances for early detection and treatment of cancer.”

### **About Fujirebio Diagnostics, Inc.**

Fujirebio Diagnostics, Inc.(FDI), is a premier diagnostics company and the industry leader in Tumor Marker assays specializing in the clinical development, manufacturing and commercialization of *in vitro* diagnostic products for the detection, prognosis, and monitoring of human disease states with an emphasis in Oncology. The company, formerly known as Centocor Diagnostics, was acquired by Fujirebio, Inc. of Tokyo, Japan in November 1998. FDI utilizes its world wide distribution network to enable access by physicians and patients to its diagnostic products.

### **About Yale School of Medicine and Yale Cancer Center**

Since its founding in 1810, Yale University School of Medicine has made major contributions to public health by isolating the polio virus, promoting the early use of cancer chemotherapy, adding to the arsenal of AIDS medications, developing a promising Lyme disease vaccine, discovering genes that contribute to skin cancer and high blood pressure, and making breakthroughs in the treatment of Parkinson's disease, depression and other mental disorders.

Yale Cancer Center is one of a select network of 41 comprehensive cancer centers in the country designated by the National Cancer Institute and the only one in Southern New England. The Center harnesses the scientific resources of Yale University School of Medicine, Yale-New Haven Hospital, and Yale University. Led by Dr. Vincent T. DeVita, Jr., a former director of the National Cancer Institute, Yale Cancer Center focuses on translational research, an approach through which laboratory discoveries are quickly and efficiently integrated with clinical patient care. The Center supports 13 multi-disciplinary research programs and 15 shared resource facilities.

###